Breaking World Pharma News

Eating a Mediterranean diet could cut womb cancer risk

Women who eat a Mediterranean diet could cut their risk of womb cancer by more than half (57 per cent), according to a study published today in the British Journal of Cancer. The Italian researchers looked at the diets of over 5,000 Italian women to see how closely they stuck to a Mediterranean diet and whether they went on to develop womb cancer.

Read more...

Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment

Boehringer IngelheimEureka Therapeutics Inc. and Boehringer Ingelheim announced have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology. Eureka Therapeutics will apply its proprietary human sequence antibody libraries and its unique technology platform to identify antibodies recognizing intracellular proteins, which represent approximately 90% of cancer-specific targets.

Read more...

Discovery of a treatment to block the progression of multiple sclerosis

A drug that could halt the progression of multiple sclerosis may soon be developed thanks to a discovery by a team at the CHUM Research Centre and the University of Montreal. The researchers have identified a molecule called MCAM, and they have shown that blocking this molecule could delay the onset of the disease and significantly slow its progression.

Read more...

AstraZeneca provides update on brodalumab development programme

AstraZenecaAmgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.

Read more...

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors

NovartisNovartis announced today that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care[1].

Read more...

Caffeine intake associated with reduced levels of erectile dysfunction

Men who drink the equivalent caffeine level of two to three cups of coffee a day are less likely to have erectile dysfunction (ED), according to researchers from The University of Texas Health Science Center at Houston (UTHealth). The results of a study published recently in PLOS ONE found that men who consumed between 85 and 170 milligrams of caffeine a day were 42 percent less likely to report ED,

Read more...

Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate

Boehringer IngelheimBoehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]